Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration

Enrico Borrelli,Giulia Coco,Marco Pellegrini,Marco Mura,Nicolò Ciarmatori,Vincenzo Scorcia,Adriano Carnevali,Andrea Lucisano,Massimiliano Borselli,Costanza Rossi,Michele Reibaldi,Federico Ricardi,Aldo Vagge,Massimo Nicolò,Paolo Forte,Antonio Cartabellotta,Murat Hasanreisoğlu,Cem Kesim,Sibel Demirel,Özge Yanık,Federico Bernabei,Pierre-Raphael Rothschild,Sarah Farrant,Giuseppe Giannaccare
DOI: https://doi.org/10.1007/s40123-024-01030-w
2024-09-15
Ophthalmology and Therapy
Abstract:Photobiomodulation (PBM) has become a promising approach for slowing the progression of early and intermediate dry age-related macular degeneration (dAMD) to advanced AMD. This technique uses light to penetrate tissues and activate molecules that influence biochemical reactions and cellular metabolism. This preliminary analysis is aimed at assessing the safety, tolerability, and short-term effectiveness of the EYE-LIGHT ® PBM treatment device in patients with dAMD.
ophthalmology
What problem does this paper attempt to address?